{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T19:42:52Z","timestamp":1786304572174,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K15234"],"award-info":[{"award-number":["JP23K15234"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijoms.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijom.2026.02.022","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:28:22Z","timestamp":1773088102000},"page":"1041-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medication-related osteonecrosis of the jaw with severe soft tissue necrosis associated with osimertinib therapy"],"prefix":"10.1016","volume":"55","author":[{"given":"H.","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijom.2026.02.022_bib1","doi-asserted-by":"crossref","first-page":"75712","DOI":"10.18632\/oncotarget.20095","article-title":"EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer","volume":"8","author":"Nan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijom.2026.02.022_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ijc.32097","article-title":"Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: a meta-analysis","volume":"145","author":"Yi","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijom.2026.02.022_bib3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2026.02.022_bib4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/ijc.32399","article-title":"Osimertinib and jaw osteonecrosis? A case report","volume":"145","author":"Subramanian","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijom.2026.02.022_bib5","article-title":"Osimertinib: another medication related to osteonecrosis of the jaws? A case report and literature review","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijom.2026.02.022_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.adaj.2021.12.008","article-title":"Emerging antiresorptive medications and their potential implications for dental surgeries","volume":"153","author":"Aminoshariae","year":"2022","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.ijom.2026.02.022_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5794\/jjoms.71.70","article-title":"A case of osteonecrosis of the jaw with soft tissue necrosis due to osimertinib","volume":"71","author":"Hayashi","year":"2025","journal-title":"Jpn J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2026.02.022_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijom.2026.02.022_bib9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijom.2026.02.022_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1677\/erc.1.00956","article-title":"Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ijom.2026.02.022_bib11","article-title":"Osimertinib-induced cutaneous vasculitis responsive to low-dose dapsone without interruption of anticancer therapy: a case report and review of the literature","volume":"3","author":"Iriarte","year":"2022","journal-title":"JTO Clin Res Rep"}],"container-title":["International Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502726000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502726000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T19:28:13Z","timestamp":1786303693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0901502726000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0901502726000834"],"URL":"https:\/\/doi.org\/10.1016\/j.ijom.2026.02.022","relation":{},"ISSN":["0901-5027"],"issn-type":[{"value":"0901-5027","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw with severe soft tissue necrosis associated with osimertinib therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijom.2026.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}